The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Considering Benzbromarone as First-Line Therapy for Gout

Considering Benzbromarone as First-Line Therapy for Gout

December 1, 2022 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Background & Objectives

In patients with gout, increased serum urate, (i.e., hyperuricemia), promotes crystal deposition of monosodium urate monohydrate crystals in articular and periarticular structures, which can trigger acute episodes of very painful inflammatory arthritis. The predominant mechanism driving hyperuricemia in gout is the underexcretion of renal uric acid; however, uric acid overproduction and intestinal uric acid underexcretion with renal uric acid overload can also drive hyperuricemia, alone or in combination with renal uric acid underexcretion.

You Might Also Like
  • Updates on ACR Gout Guideline, FDA’s Febuxostat Warning & Pegloticase Therapy
  • Contemporary Prevalence of Gout & Hyperuricemia in the U.S.
  • Gout Management Recommendations from the ACR’s 2020 Guideline

Based on available evidence to date, both the ACR and EULAR guidelines for the first-line management of gout recommend urate-lowering therapy with a xanthine oxidase inhibitor (e.g., allopurinol or febuxostat), irrespective of the cause of the hyperuricemia. Whereas the 2016 EULAR guidelines recommend uricosuric therapy with an agent that inhibits renal urate transporter 1 (URAT1) (e.g., benzbromarone or probenecid) as a second-line urate-lowering therapy option, the 2020 ACR guideline only provides a conditional recommendation for probenecid use as a second-line agent after treatment failure with allopurinol. Because benzbromarone is not approved for use in the U.S., it is not included in the ACR recommendation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In this comparative effectiveness clinical trial, Yan et al. set out to compare nontitrated, low-dose benzbromarone with low-dose febuxostat as the first-line therapy in gout patients with renal uric acid underexcretion.

Methods

Yan et al. conducted a prospective, randomized, single-center, open-label trial in men with gout and renal uric acid underexcretion (defined as fractional excretion of urate <5.5% and uric acid excretion ≤600 mg/day/1.73 m2). A total of 196 participants were randomly assigned to receive low-dose benzbromarone 25 mg daily or low-dose febuxostat 20 mg daily for 12 weeks. All participants received daily urine alkalization with oral sodium bicarbonate. The primary end point was the rate of achieving the serum urate target of <6 mg/dL.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Results

More participants in the low-dose benzbromarone group achieved the serum urate target than those in the low-dose febuxostat group (61% compared with 32%, P<0.001). Rates of adverse events, including gout flares and urolithiasis, did not differ between groups, with the exception of greater transaminase elevation in the low-dose febuxostat group (4% for low-dose benzbromarone compared with 15% for low-dose febuxostat, P=0.008).

Conclusion

Compared with low-dose febuxostat, low-dose benzbromarone has superior urate-lowering and similar safety in relatively young and healthy patients with renal uric acid underexcretion-type gout.

Further investigation is warranted to test precision in the model for use of a URAT1 inhibitor in selecting a first-line urate-lowering therapy according to primary renal uric acid underexcretion, as opposed to decreased renal function. However, the results suggest that low-dose benzbromarone may warrant consideration as a safe and effective therapy to achieve serum urate target in gout patients without moderate chronic kidney disease.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions, Crystal Arthritis, Drug Updates Tagged With: Arthritis & Rheumatology, benzbromarone, Febuxostat, Gout, Gout Resource Center, hyperuricemia

You Might Also Like:
  • Updates on ACR Gout Guideline, FDA’s Febuxostat Warning & Pegloticase Therapy
  • Contemporary Prevalence of Gout & Hyperuricemia in the U.S.
  • Gout Management Recommendations from the ACR’s 2020 Guideline
  • Lesinurad with Allopurinol When Allopurinol Alone Is Insufficient

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)